[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Wyss MT, Hofer S, Hefti M, Bärtschi E, Uhlmann C, Treyer V, Roelcke U: Spatial heterogeneity of low-grade gliomas at the capillary level: a PET study on tumor blood flow and amino acid uptake. J Nucl Med; 2007 Jul;48(7):1047-52
Hazardous Substances Data Bank. Water .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spatial heterogeneity of low-grade gliomas at the capillary level: a PET study on tumor blood flow and amino acid uptake.
  • Many low-grade gliomas (World Health Organization grade II) respond to chemotherapy.
  • Cerebral blood flow (CBF) and microvessel density may be critical for drug delivery.
  • We used PET with (18)F-fluoro-ethyl-l-tyrosine (FET) to measure the spatial distribution of the amino acid carrier, which is located at the brain capillaries, and (15)O-H(2)O to measure tumor CBF.
  • Region-of-interest (ROI) analysis was used to quantify tumor tracer uptake, which was normalized to cerebellar uptake (tumor-to-cerebellum ratio).
  • "Active" tumor was defined as tumor having a radioactivity concentration that was at least 110% of the cerebellar activity.
  • This threshold provided measures of active tumor volume, global and peak tumor CBF, and (18)F-FET uptake.
  • Trace ROIs were applied to create voxelwise profiles of CBF and (18)F-FET uptake across tumor and brain.
  • RESULTS: Fourteen of 17 tumors showed increased global CBF and (18)F-FET uptake.
  • Active tumor volumes ranged between 3 and 270 cm(3) for (18)F-FET and between 1 and 41 cm(3) for CBF.
  • Global (18)F-FET uptake in tumors corresponded to CBF increases (Spearman rank rho = 0.771, P < 0.01).
  • Trace ROIs showed that irrespective of increased (18)F-FET uptake at the tumor periphery, CBF increases were more confined to the tumor center.
  • Within individual tumors, spatial heterogeneity was present.
  • Particular tumors infiltrating the corpus callosum showed low CBF and (18)F-FET uptake in this tumor region.
  • The patterns observed with PET were not reflected on MRI of the tumors, all of which presented as homogeneous non-gadolinium-enhancing lesions.
  • CONCLUSION: Low-grade gliomas are heterogeneous tumors with regard to the distribution of amino acid uptake and CBF.
  • Both are coupled in the tumor center.
  • At the tumor periphery, where tumor infiltration of surrounding brain occurs, CBF may be low irrespective of increased (18)F-FET uptake.
  • An ongoing study is investigating the effect of chemotherapy on these observations.
  • [MeSH-major] Brain Neoplasms / blood supply. Glioma / blood supply. Radiopharmaceuticals / pharmacokinetics. Tyrosine / analogs & derivatives
  • [MeSH-minor] Adult. Amino Acid Transport Systems / metabolism. Capillaries / metabolism. Capillaries / radionuclide imaging. Cerebellum / blood supply. Cerebellum / metabolism. Cerebellum / radionuclide imaging. Female. Fluorine Radioisotopes. Humans. Male. Microcirculation / metabolism. Microcirculation / radionuclide imaging. Middle Aged. Oxygen Isotopes. Oxygen Radioisotopes. Positron-Emission Tomography. Water

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. L-TYROSINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17574979.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acid Transport Systems; 0 / Fluorine Radioisotopes; 0 / O-(2-fluoroethyl)tyrosine; 0 / Oxygen Isotopes; 0 / Oxygen Radioisotopes; 0 / Radiopharmaceuticals; 059QF0KO0R / Water; 42HK56048U / Tyrosine
  •  go-up   go-down


2. Hur H, Jung S, Jung TY, Kim IY: Cerebellar glioblastoma multiforme in an adult. J Korean Neurosurg Soc; 2008 Apr;43(4):194-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebellar glioblastoma multiforme in an adult.
  • Primary cerebellar glioblastoma multiforme (GBM) is a rare tumor in adults that accounts for just 1% of all cases of GBM.
  • Due to their rarity, cerebellar GBMs are not yet completely understood about the pathogenesis and the prognosis.
  • Neurologic examination revealed the presence of cerebellar signs.
  • Magnetic resonance imaging (MRI) showed a 4.5 x 3.6 cm-sized, ill-defined, heterogeneously enhancing mass in the left cerebellum and two patchy hyperintense lesions in the right cerebellum with minimal enhancement.
  • Postoperative radiotherapy with concomitant and adjuvant temozolomide chemotherapy was subsequently followed.
  • Here, a case of unusual GBM in the cerebellum is reported with review of literature regarding the pathogenesis, the differential diagnosis and prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Interv Radiol. 2005 Jun;11(2):83-6 [15957093.001]
  • [Cites] Radiology. 2002 Mar;222(3):715-21 [11867790.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 Mar;16(3):583-9 [7793385.001]
  • [Cites] J Comput Assist Tomogr. 1991 Jan-Feb;15(1):160-2 [1987190.001]
  • [Cites] J Neurosurg. 1987 Dec;67(6):915-8 [2824720.001]
  • [Cites] J Neurosurg Sci. 1985 Jan-Mar;29(1):43-50 [2999352.001]
  • [Cites] Arq Neuropsiquiatr. 1985 Mar;43(1):102-7 [2990393.001]
  • [Cites] J Neurooncol. 1989 Nov;7(4):339-44 [2555454.001]
  • [Cites] Tumori. 1989 Dec 31;75(6):626-9 [2559527.001]
  • [Cites] Neurosurgery. 1987 Aug;21(2):251-5 [3309714.001]
  • [Cites] Br J Radiol. 1985 May;58(689):480-2 [4063702.001]
  • [Cites] Semin Roentgenol. 1990 Jul;25(3):263-78 [2385809.001]
  • [Cites] Semin Roentgenol. 1990 Apr;25(2):155-73 [2349487.001]
  • [Cites] J Neurosurg. 1983 Apr;58(4):589-92 [6298382.001]
  • [Cites] Surg Neurol. 1983 Apr;19(4):373-8 [6301087.001]
  • [Cites] Arq Neuropsiquiatr. 1981 Sep;39(3):350-4 [6275825.001]
  • [Cites] Cancer. 1982 Jul 15;50(2):308-11 [6282439.001]
  • [Cites] Acta Neurochir (Wien). 1980;53(1-2):107-16 [6254346.001]
  • [Cites] Surg Neurol. 1976 Jun;5(6):341-3 [180621.001]
  • [Cites] J Chin Med Assoc. 2004 Jun;67(6):301-4 [15366408.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 Sep;23(8):1369-77 [12223380.001]
  • [Cites] J Neurosurg. 1999 Mar;90(3):546-50 [10067927.001]
  • (PMID = 19096643.001).
  • [ISSN] 2005-3711
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2588262
  • [Keywords] NOTNLM ; Cerebellum / Differential diagnosis / Glioblastoma multiforme / Pathogenesis
  •  go-up   go-down


3. Merchant TE, Kun LE, Wu S, Xiong X, Sanford RA, Boop FA: Phase II trial of conformal radiation therapy for pediatric low-grade glioma. J Clin Oncol; 2009 Aug 1;27(22):3598-604
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of conformal radiation therapy for pediatric low-grade glioma.
  • We conducted a phase II trial of conformal radiation therapy (CRT) to estimate disease control by using a 10-mm clinical target volume (CTV) margin.
  • MATERIALS AND METHODS: Between August 1997 and August 2006, 78 pediatric patients with LGG and a median age of 8.9 years (range, 2.2 to 19.8 years) received 54 Gy CRT by using a 10-mm CTV and by targeting with systematic magnetic resonance imaging (MRI) registration.
  • Tumor locations were diencephalon (n = 58), cerebral hemisphere (n = 3), and cerebellum (n = 17).
  • Sixty-seven patients had documented or presumed WHO grade 1 tumors, 25 patients had prior chemotherapy, and 13 patients had neurofibromatosis type 1.
  • One patient experienced marginal treatment failure, eight experienced local failures, and four experienced metastatic failure.
  • The mean and standard error cumulative incidence of vasculopathy was 4.79% +/- 2.73% at 6 years, and it was higher for those younger than 5 years of age (P = .0105) at the time of CRT.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / radiotherapy. Glioma / mortality. Glioma / radiotherapy. Neoplasm Invasiveness / pathology. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adolescent. Age Factors. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Dose-Response Relationship, Radiation. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Magnetic Resonance Angiography. Male. Neoplasm Staging. Prognosis. Prospective Studies. Radiotherapy Dosage. Risk Assessment. Statistics, Nonparametric. Survival Analysis. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1999 Oct 21;18(43):5870-8 [10557074.001]
  • [Cites] J Clin Oncol. 2009 Aug 1;27(22):3691-7 [19581535.001]
  • [Cites] Pediatr Neurosurg. 2000 Mar;32(3):154-62 [10867564.001]
  • [Cites] Semin Radiat Oncol. 2001 Apr;11(2):124-37 [11285550.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):325-32 [11872277.001]
  • [Cites] Strahlenther Onkol. 2002 Jan;178(1):10-7 [11977386.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):43-51 [12007940.001]
  • [Cites] J Clin Oncol. 2002 Oct 15;20(20):4209-16 [12377964.001]
  • [Cites] Brain. 2003 Jan;126(Pt 1):152-60 [12477702.001]
  • [Cites] Pediatr Radiol. 2003 Mar;33(3):207-10 [12612823.001]
  • [Cites] Neuro Oncol. 2003 Jul;5(3):153-60 [12816721.001]
  • [Cites] Strahlenther Onkol. 2003 Aug;179(8):509-20 [14509949.001]
  • [Cites] Strahlenther Onkol. 2003 Sep;179(9):585-97 [14628124.001]
  • [Cites] J Neuroophthalmol. 2004 Sep;24(3):206-10 [15348985.001]
  • [Cites] J Neurosurg. 1978 Jul;49(1):22-35 [660265.001]
  • [Cites] Childs Brain. 1983;10(6):393-403 [6661937.001]
  • [Cites] J Neurosurg. 1988 Aug;69(2):171-6 [3392563.001]
  • [Cites] Eur J Pediatr. 1990 Sep;149(12):825-8 [2226566.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Mar 30;28(5):1229-34 [8175410.001]
  • [Cites] Cancer. 1995 Feb 15;75(4):1051-9 [7842408.001]
  • [Cites] J Neurosurg. 1995 Oct;83(4):583-9 [7674005.001]
  • [Cites] Childs Nerv Syst. 1995 Aug;11(8):443-8 [7585679.001]
  • [Cites] J Neurooncol. 1997 May;32(3):235-41 [9049885.001]
  • [Cites] J Neurosurg. 1997 May;86(5):747-54 [9126887.001]
  • [Cites] Radiother Oncol. 1997 Oct;45(1):11-5 [9364626.001]
  • [Cites] Ann Neurol. 1999 Mar;45(3):393-6 [10072056.001]
  • [Cites] Klin Padiatr. 2004 Nov-Dec;216(6):331-42 [15565548.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):374-9 [15667955.001]
  • [Cites] Neurosurg Focus. 2003 May 15;14(5):e15 [15669811.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5198-204 [16051961.001]
  • [Cites] Technol Cancer Res Treat. 2006 Feb;5(1):1-8 [16417396.001]
  • [Cites] Neuro Oncol. 2006 Apr;8(2):166-74 [16495375.001]
  • [Cites] Rev Neurol. 2008 May 1-15;46(9):530-6 [18446694.001]
  • [Cites] Arch Pathol Lab Med. 2008 Jun;132(6):993-1007 [18517285.001]
  • [Cites] Pediatr Blood Cancer. 2008 Aug;51(2):245-50 [18386785.001]
  • [Cites] Radiother Oncol. 2000 Mar;54(3):239-45 [10738082.001]
  • (PMID = 19581536.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3525947
  •  go-up   go-down


Advertisement
4. Hukin J, Siffert J, Velasquez L, Zagzag D, Allen J: Leptomeningeal dissemination in children with progressive low-grade neuroepithelial tumors. Neuro Oncol; 2002 10;4(4):253-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptomeningeal dissemination in children with progressive low-grade neuroepithelial tumors.
  • Our purpose is to describe the incidence and clinical features of leptomeningeal dissemination (LM) in children with progressive low-grade neuroepithelial tumor (LGN).
  • We have continuously tracked all patients with primary CNS tumors since 1986.
  • Satisfactorily followed data were obtained on 427 of the 588 patients with localized LGN at diagnosis between 1986 and 1998, 177 (42%) of whom developed progressive or recurrent disease.
  • The primary tumor sites were diencephalon (6), brainstem (3), cerebellum (2), cerebrum (1), and spinal cord (1).
  • Management included chemotherapy (2) or radiotherapy (3) or both (7); 1 patient received only radical resections of symptomatic lesions.
  • Tumors arising from the diencephalon appeared to predispose to LM; no other predisposing features were identified.
  • We strongly urge that for optimum treatment planning all patients with recurrent LGN be staged with an enhanced spine and brain MRI before adjuvant therapy is initiated.
  • The good survival of patients with LGN and LM reflects a more indolent disease than malignant CNS tumors with LM.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Meningeal Neoplasms / secondary. Neoplasms, Neuroepithelial / secondary
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Disease Progression. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / therapy. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12356355.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1920666
  •  go-up   go-down


5. Baehring JM, Henchcliffe C, Ledezma CJ, Fulbright R, Hochberg FH: Intravascular lymphoma: magnetic resonance imaging correlates of disease dynamics within the central nervous system. J Neurol Neurosurg Psychiatry; 2005 Apr;76(4):540-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An advanced magnetic resonance imaging (MRI) protocol was performed at various time points prior to diagnosis and during treatment.
  • RESULTS: MRI revealed multiple lesions scattered throughout the cerebral hemispheres; the brainstem, cerebellum, and spinal cord were less frequently involved.
  • On initial presentation, hyperintense lesions were seen on diffusion weighted images suggestive of ischaemia in three of four patients in whom the images were obtained at that time point.
  • Diffusion weighted imaging lesions either vanished or followed the typical pattern of an ischaemic small vessel stroke with evolution of abnormal FLAIR signal followed by enhancement with gadolinium in the subacute stage and tissue loss in the chronic stage.
  • Diffusion weighted imaging and FLAIR abnormalities proved to be partially reversible, correlating with the response to chemotherapy.
  • These patterns in combination with systemic findings may facilitate early diagnosis and serve as a new tool to monitor treatment response.
  • [MeSH-major] Brain Neoplasms / pathology. Diffusion Magnetic Resonance Imaging. Lymphoma, Non-Hodgkin / pathology. Vascular Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD / immunology. Biopsy. Brain / pathology. Cervical Vertebrae / pathology. Cognition Disorders / diagnosis. Cognition Disorders / etiology. Diagnosis, Differential. Disease Progression. Female. Functional Laterality. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Paraparesis / diagnosis. Paraparesis / etiology. Psychotic Disorders / diagnosis. Psychotic Disorders / etiology. Retrospective Studies. Thoracic Vertebrae / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Exp Med Biol. 1999;455:249-65 [10599352.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):355-8 [9950508.001]
  • [Cites] Neuroradiology. 2000 Jun;42(6):436-40 [10929304.001]
  • [Cites] Radiology. 2000 Nov;217(2):331-45 [11058626.001]
  • [Cites] Clin Imaging. 2000 Jul-Aug;24(4):181-92 [11274879.001]
  • [Cites] J Neurooncol. 2001 Jan;51(1):47-50 [11349880.001]
  • [Cites] Neuroradiology. 2002 Sep;44(9):749-54 [12221446.001]
  • [Cites] J Neurooncol. 2003 Feb;61(3):237-48 [12675317.001]
  • [Cites] Eur Radiol. 2003 Jul;13(7):1753-5 [12899134.001]
  • [Cites] Cancer. 1993 May 15;71(10):3156-64 [8490846.001]
  • [Cites] J Cancer Res Clin Oncol. 1994;120(3):164-8 [8263013.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1738-45 [8156502.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2573-9 [7989931.001]
  • [Cites] Clin Lab Haematol. 1994 Dec;16(4):363-9 [7736714.001]
  • [Cites] J Rheumatol. 1995 Sep;22(9):1769-70 [8523360.001]
  • [Cites] AJNR Am J Neuroradiol. 1998 Mar;19(3):427-31 [9541293.001]
  • [Cites] J Neuroimaging. 1998 Apr;8(2):110-3 [9557152.001]
  • [Cites] J Neuroimaging. 2000 Apr;10(2):116-8 [10800265.001]
  • (PMID = 15774442.001).
  • [ISSN] 0022-3050
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD
  • [Other-IDs] NLM/ PMC1739607
  •  go-up   go-down


6. Johnson MD, Moots PL, Zhuang Z, Weil RJ: Molecular genetic analysis of a primitive neuroectodermal tumor arising after intracranial radiation and chemotherapy for leukemia. Ann Clin Lab Sci; 2009;39(3):295-302
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular genetic analysis of a primitive neuroectodermal tumor arising after intracranial radiation and chemotherapy for leukemia.
  • Primitive neuroectodermal tumors are aggressive tumors of the central nervous system (CNS), yet their etiology remains unclear.
  • We report a case of a primitive neuroectodermal tumor (PNET) arising in the cerebellum and pons 7 yr after intracranial radiation and chemotherapy for leukemia involving the CNS.
  • This case suggests a possible link between radiation, chemotherapy, and the formation of these tumors, with a potential new pathogenetic role for somatic inactivation of the protooncogene RET.
  • [MeSH-major] Cranial Irradiation / adverse effects. Neuroectodermal Tumors, Primitive / etiology. Neuroectodermal Tumors, Primitive / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy
  • [MeSH-minor] Adult. Bone Marrow Transplantation. Brain / pathology. Chromosomes, Human, Pair 10 / genetics. Chromosomes, Human, Pair 17 / genetics. Humans. Loss of Heterozygosity / genetics. Magnetic Resonance Imaging. Male. Methotrexate / administration & dosage. Methotrexate / therapeutic use. PTEN Phosphohydrolase / genetics. Proto-Oncogene Proteins c-ret / genetics. Tumor Suppressor Protein p53 / genetics. Whole-Body Irradiation

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19667415.001).
  • [ISSN] 1550-8080
  • [Journal-full-title] Annals of clinical and laboratory science
  • [ISO-abbreviation] Ann. Clin. Lab. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


7. Tang BN, Sadeghi N, Branle F, De Witte O, Wikler D, Goldman S: Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma. J Neurooncol; 2005 Jan;71(2):161-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma.
  • 11C-Methionine (MET) is a useful positron emission tomography (PET) tracer for the evaluation of low-grade gliomas.
  • Among these tumors, a high percentage of low-grade oligodendrogliomas (ODG) are sensitive to chemotherapy with procarbazine, CCNU, and vincristine (PCV). We aimed at:.
  • METHODS: seven patients with ODG were followed for a period of 19.9+/-6.6 months after the completion of PCV chemotherapy.
  • Regions of interest (ROI) were generated by covering all voxels with count values above a threshold level set at 120% of the mean cerebellar activity.
  • AVI was calculated as the sum over all ROI of tumor volumex(tumor mean count/cerebellum count).
  • Tumor volume measurements on MRI, were based on signal abnormalities visually detected on fluid-attenuated inversion recovery (FLAIR) sequences.
  • RESULTS: PCV therapy was associated with a drastic decrease in AVI (mean+/-SD, cm3): AVI post-PCV=0.80+/-1.45 vs. AVI prior PCV=12.94+/-11.46 (P=0.03).
  • Likewise, we observed a decrease in tumor volume estimated from the FLAIR signal (31.37+/-11.99 post-PCV vs. 67.95+/-39.96 prior PCV, P=0.03) although AVI decrease after PCV was significantly more pronounced (P=0.015).
  • CONCLUSION: This study, based on limited number of patients and follow-up period indicates that AVI may be a sensitive and observer-independent method applicable to the assessment of ODG responsiveness to PCV treatment and may offer a major added value to both clinical assessment and MRI evaluation of chemotherapeutic outcomes.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Lomustine / therapeutic use. Magnetic Resonance Imaging. Methionine / pharmacokinetics. Oligodendroglioma / drug therapy. Positron-Emission Tomography. Procarbazine / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. (L)-Methionine .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2001 Oct;55(1):45-50 [11804282.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] Surg Neurol. 1993 Jun;39(6):458-65 [8390726.001]
  • [Cites] J Neurooncol. 1986;3(4):397-404 [3485705.001]
  • [Cites] Neurology. 1996 Jan;46(1):203-7 [8559376.001]
  • [Cites] Eur J Nucl Med. 1976;1(1):11-4 [1017425.001]
  • [Cites] J Neurooncol. 1997 Aug;34(1):37-59 [9210052.001]
  • [Cites] Am J Pathol. 1994 Nov;145(5):1175-90 [7977648.001]
  • [Cites] J Neurosurg. 2002 Dec;97(5 Suppl):542-50 [12507094.001]
  • [Cites] J Comput Assist Tomogr. 1985 Jul-Aug;9(4):683-9 [3926834.001]
  • [Cites] J Neurooncol. 1998 Dec;40(3):251-5 [10066098.001]
  • [Cites] Cancer. 2003 May 1;97(9):2254-61 [12712480.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):251-5 [12525516.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Feb;17 (2):345-53 [8938309.001]
  • [Cites] Neurology. 1998 Oct;51(4):1140-5 [9781544.001]
  • [Cites] Bull Mem Acad R Med Belg. 2002;157(7-9):355-62; discussion 363-9 [12647376.001]
  • [Cites] Eur Radiol. 2001;11(10):2004-10 [11702135.001]
  • [Cites] Physiol Rev. 1983 Oct;63(4):1481-535 [6361813.001]
  • [Cites] Neurology. 1998 May;50(5):1316-22 [9595980.001]
  • [Cites] J Neurosurg. 1992 May;76(5):741-5 [1564535.001]
  • [Cites] J Nucl Med. 2000 Jul;41(7):1250-5 [10914918.001]
  • [Cites] Neurology. 2002 Sep 24;59(6):947-9 [12297589.001]
  • [Cites] Neuroradiology. 2001 Feb;43(2):129-33 [11326557.001]
  • [Cites] J Neurosurg. 2001 Nov;95(5):746-50 [11702862.001]
  • [Cites] J Nucl Med. 1997 Sep;38(9):1459-62 [9293808.001]
  • [Cites] J Neuroimaging. 2003 Jul;13(3):269-71 [12889176.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Jun-Jul;17(6):1081-6 [8791919.001]
  • [Cites] Cell Mol Neurobiol. 1995 Jun;15(3):351-60 [7553734.001]
  • [Cites] J Nucl Med. 1998 May;39(5):778-85 [9591574.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):276-87; discussion 287-8 [9007859.001]
  • [Cites] Stereotact Funct Neurosurg. 1997;69(1-4 Pt 2):129-35 [9711745.001]
  • [Cites] Curr Treat Options Oncol. 2001 Dec;2(6):495-506 [12057095.001]
  • [Cites] Arch Neurol. 1991 Feb;48(2):225-7 [1993014.001]
  • (PMID = 15690133.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; AE28F7PNPL / Methionine; PCV protocol
  •  go-up   go-down


8. Fukushima S, Terasaki M, Tajima Y, Shigemori M: Granulocytic sarcoma: an unusual complication of acute promyelocytic leukemia causing cerebellar hemorrhage. Case report. J Neurosurg; 2006 Dec;105(6):912-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma: an unusual complication of acute promyelocytic leukemia causing cerebellar hemorrhage. Case report.
  • Granulocytic sarcomas are rare tumors that occur primarily in patients with acute myelogenous leukemia or other myeloproliferative disorders, are seldom seen in patients with acute promyelocytic leukemia (APL), and have never been reported to occur in the cerebellum.
  • The authors describe the case of a patient with APL who harbored a hemorrhagic granulocytic sarcoma in the cerebellum.
  • This 39-year-old woman presented with cerebellar ataxia.
  • Magnetic resonance images revealed an intraaxial tumor in the cerebellum.
  • The patient was treated with chemotherapy and surgery.
  • She had no response to chemotherapy and died of progressive intratumoral hemorrhage.
  • Results of histopathological studies and immunohistochemical staining of the cerebellar tumor confirmed a granulocytic sarcoma.
  • This is the first report to document a granulocytic sarcoma in the cerebellum as the primary presentation in a patient with APL and abnormal coagulation.
  • Although central nervous system complications in patients with APL are rare, the data in this case highlight the need for individualized treatment when such conditions occur.
  • [MeSH-major] Cerebellar Neoplasms / etiology. Cerebral Hemorrhage / etiology. Leukemia, Promyelocytic, Acute / complications. Sarcoma, Myeloid / etiology
  • [MeSH-minor] Adult. Bone Marrow / pathology. Cerebellar Ataxia / etiology. Cerebellum / pathology. Chimera / genetics. Female. Gene Fusion / genetics. Granulocyte Precursor Cells / pathology. Humans. Inclusion Bodies / pathology. Karyotyping. Magnetic Resonance Imaging. Receptors, Retinoic Acid / genetics

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17405265.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Retinoic Acid; 0 / retinoic acid receptor alpha
  •  go-up   go-down


9. Endo H, Kumabe T, Jokura H, Shirane R, Ariga H, Takai Y, Yoshimoto T: Leptomeningeal dissemination of cerebellar malignant astrocytomas. J Neurooncol; 2003 Jun;63(2):191-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptomeningeal dissemination of cerebellar malignant astrocytomas.
  • Primary malignant astrocytomas of the cerebellum are extremely rare, and the dissemination patterns and effectiveness of postoperative radiation therapy are unclear.
  • Five consecutive cases of histologically proven cerebellar malignant astrocytoma, two anaplastic astrocytomas, one anaplastic pilocytic astrocytoma, and two glioblastomas, were treated between 1997 and 2001.
  • Four patients underwent surgical removal, local irradiation, and chemotherapy, and one patient with anaplastic pilocytic astrocytoma received subtotal removal followed by gamma knife radiosurgery for the residual tumor.
  • All patients developed leptomeningeal dissemination.
  • The time interval between the diagnosis of the primary cerebellar tumor and the diagnosis of leptomeningeal dissemination was 5-29 months (mean 14.6 +/- 10.4 months).
  • Intensive treatment including chemotherapy and radiotherapy may be required in cerebellar malignant astrocytomas, considering the high incidence of symptomatic leptomeningeal dissemination.
  • [MeSH-major] Astrocytoma / secondary. Cerebellar Neoplasms / pathology. Meningeal Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Cerebral Ventricles / pathology. Child. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1981 Dec;7(12):1661-5 [6977517.001]
  • [Cites] Ann Oncol. 2001 Feb;12 (2):259-66 [11300335.001]
  • [Cites] J Neurosurg. 1976 Apr;44(4):442-8 [176331.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):9-17 [3964859.001]
  • [Cites] West Engl Med J. 1990 Jun;105(2):39-42 [2173942.001]
  • [Cites] Neurosurgery. 1986 Aug;19(2):247-51 [3748352.001]
  • [Cites] J Neurooncol. 1987;5(3):231-6 [2824711.001]
  • [Cites] J Neurosurg. 1983 Apr;58(4):589-92 [6298382.001]
  • [Cites] J Neurosurg. 1999 Mar;90(3):546-50 [10067927.001]
  • [Cites] J Clin Neurosci. 2004 Jan;11(1):37-41 [14642363.001]
  • [Cites] Clin Imaging. 1995 Jul-Sep;19(3):162-4 [7553429.001]
  • [Cites] Cancer. 1982 Jul 15;50(2):308-11 [6282439.001]
  • [Cites] Acta Neurochir (Wien). 1980;53(1-2):107-16 [6254346.001]
  • [Cites] J Neurosurg. 1976 Dec;45(6):705-8 [185342.001]
  • [Cites] J Neurooncol. 1989 Jul;7(2):165-77 [2550594.001]
  • [Cites] Surg Neurol. 1983 Apr;19(4):373-8 [6301087.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 Mar;16(3):583-9 [7793385.001]
  • [Cites] J Neurooncol. 1998 Feb;36(3):247-57 [9524103.001]
  • [Cites] Cancer. 1990 Jan 15;65(2):337-40 [2295056.001]
  • [Cites] Acta Neurochir (Wien). 1989;98 (1-2):1-8 [2741731.001]
  • [Cites] Acta Neurochir (Wien). 1994;126(2-4):84-92 [8042560.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1982 Jun;8(6):999-1003 [7107442.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] J Neurooncol. 1984;2(1):79-84 [6088728.001]
  • [Cites] Neurosurgery. 1982 Feb;10(2):252-7 [6280098.001]
  • [Cites] Neurosurgery. 1990 Oct;27(4):516-21; discussion 521-2 [2172859.001]
  • [Cites] Ann Neurol. 1980 Dec;8(6):605-8 [6260012.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1976 Jul-Aug;1(7-8):627-37 [185169.001]
  • [Cites] J Neurooncol. 1983;1(3):275-8 [6088719.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Mar 15;40(5):1141-9 [9539570.001]
  • (PMID = 12825824.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Koeller KK, Rushing EJ: From the archives of the AFIP: pilocytic astrocytoma: radiologic-pathologic correlation. Radiographics; 2004 Nov-Dec;24(6):1693-708
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pilocytic astrocytoma is the most common pediatric central nervous system glial neoplasm and the most common pediatric cerebellar tumor.
  • This tumor has a noteworthy benign biologic behavior that translates into an extremely high survival rate-94% at 10 years-that is by far the best of any glial tumor.
  • Most patients present in the first 2 decades, and clinical symptoms and signs are usually of several months duration and directly related to the specific location of the tumor.
  • The cerebellum, optic nerve and chiasm, and hypothalamic region are the most common locations, but the tumor can also be found in the cerebral hemisphere, ventricles, and spinal cord.
  • Surgical resection is the treatment of choice for all tumors, except for those involving the optic pathway and hypothalamic region, which may be treated with radiation therapy and chemotherapy.
  • Accurate interpretation of imaging studies plays an essential role in directing treatment of these tumors, particularly when they arise in the optic pathway of patients with neurofibromatosis type 1.
  • [MeSH-major] Astrocytoma / pathology. Astrocytoma / radiography. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Child. Humans

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15537977.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 98
  •  go-up   go-down


11. Rorke-Adams LB, Portnoy H: Long-term survival of an infant with gliomatosis cerebelli. J Neurosurg Pediatr; 2008 Nov;2(5):346-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliomatosis cerebri is an uncommon but well-established central nervous system neoplasm that occurs primarily in adults.
  • Although the neoplastic process typically arises in the cerebrum, it often spreads to brainstem, cerebellum, or even the spinal cord.
  • In this report the authors document the surgical treatment of a 13-month-old boy whose tumor arose in the cerebellum and over time extended to the thalamus where its growth halted at age 3 years and 10 months.
  • Aside from 2 partial resections the patient underwent neither radiotherapy nor chemotherapy.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Cerebellar Neoplasms / surgery. Neoplasms, Neuroepithelial / pathology. Neoplasms, Neuroepithelial / surgery
  • [MeSH-minor] Adult. Disease-Free Survival. Humans. Infant. Male. Neoplasm Invasiveness. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18976105.001).
  • [ISSN] 1933-0707
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Nicoletti F, Arcella A, Iacovelli L, Battaglia G, Giangaspero F, Melchiorri D: Metabotropic glutamate receptors: new targets for the control of tumor growth? Trends Pharmacol Sci; 2007 May;28(5):206-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabotropic glutamate receptors: new targets for the control of tumor growth?
  • Cancer stem cells are currently a target for the treatment of malignant tumors.
  • Transformed neural stem-progenitor cells of the brain subventricular zone and the external granular layer of the cerebellum are the putative cells of origin of malignant gliomas and medulloblastomas, which are the most frequent malignant brain tumors in adults and children, respectively.
  • At least two receptor subtypes - mGlu(3) and mGlu(4) receptors - control the proliferation of brain tumor cells, whereas mGlu(1) receptors have been implicated in the development of melanomas.
  • We believe that individual mGlu receptor subtypes represent new potential targets for the treatment of several malignant tumors, including brain tumors.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Brain Neoplasms / drug therapy. Drug Delivery Systems. Receptors, Metabotropic Glutamate / drug effects
  • [MeSH-minor] Adult. Animals. Cell Proliferation. Child. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / physiopathology. Drug Resistance, Neoplasm. Gene Expression. Humans. Ligands. Melanoma / drug therapy. Melanoma / physiopathology. Neoplastic Stem Cells / drug effects. Skin Neoplasms / drug therapy. Skin Neoplasms / physiopathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17433452.001).
  • [ISSN] 0165-6147
  • [Journal-full-title] Trends in pharmacological sciences
  • [ISO-abbreviation] Trends Pharmacol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ligands; 0 / Receptors, Metabotropic Glutamate
  •  go-up   go-down


13. Hadjipanayis CG, Kondziolka D, Flickinger JC, Lunsford LD: The role of stereotactic radiosurgery for low-grade astrocytomas. Neurosurg Focus; 2003 May 15;14(5):e15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: During a 13-year interval, 49 patients underwent stereotactic radiosurgery as part of multimodal treatment of their recurrent or unresectable low-grade astrocytomas.
  • Tumors involved the brainstem in 22 cases, cerebellum in four, thalamus in six, temporal lobe in five, frontal lobe in four, and parietal lobe in three, as well as the hypothalamus, corpus callosum, insular cortex, optic tract, and third ventricle in one patient each.
  • Multimodal treatment included fractionated radiotherapy in 14 patients, stereotactic intracavitary irradiation in five, chemotherapy in two, cyst drainage in eight, ventriculoperitoneal shunt placement in five, and additional cytoreductive surgery in five.
  • Tumor volumes ranged from 0.42 to 45.1 cm3.
  • The median radiosurgical dose to the tumor margin was 15 Gy (range 9.6-22.5 Gy).
  • After radiosurgery, serial neuroimaging demonstrated complete tumor resolution in 11 patients, reduced tumor volume in 12, stable tumor volume in 10, and delayed tumor progression in 16.
  • No procedure-related death was encountered.
  • Three patients died of local tumor progression.
  • CONCLUSIONS: Stereotactic radiosurgery is a potential alternative or adjunctive intervention in the management of selected patients with pilocytic or WHO Grade II fibrillary astrocytomas, usually performed for small-volume tumors in an attempt to avoid larger-field fractionated radiotherapy.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Radiosurgery / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15669811.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Sluyter S, Graamans K, Tulleken CA, Van Veelen CW: Analysis of the results obtained in 120 patients with large acoustic neuromas surgically treated via the translabyrinthine-transtentorial approach. J Neurosurg; 2001 Jan;94(1):61-6
MedlinePlus Health Information. consumer health - Acoustic Neuroma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Complete tumor removal, as ascertained using computerized tomography or magnetic resonance imaging, was achieved in 110 patients (91.7%).
  • The main postoperative complications were cerebrospinal fluid (CSF) leakage through the scalp wound (13.3%) requiring surgical revision in 2.5%, meningitis (9.2%), CSF rhinorrhea (6.7%) requiring surgical revision in 2.5%, and epileptic seizures (the only permanent complication) requiring medication (3.3%).
  • [MeSH-minor] Adult. Aged. Anticonvulsants / therapeutic use. Cerebellum. Cerebrospinal Fluid Rhinorrhea / etiology. Cerebrospinal Fluid Rhinorrhea / surgery. Ear, Inner. Epilepsy / drug therapy. Epilepsy / etiology. Facial Nerve / physiopathology. Female. Humans. Male. Meningitis, Aseptic / etiology. Meningitis, Aseptic / surgery. Middle Aged. Postoperative Complications. Postoperative Period. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2001 Jan;94(1):144-6 [11147890.001]
  • (PMID = 11147899.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants
  •  go-up   go-down


15. Koeller KK, Rushing EJ: From the archives of the AFIP: medulloblastoma: a comprehensive review with radiologic-pathologic correlation. Radiographics; 2003 Nov-Dec;23(6):1613-37
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Medulloblastoma is the most common pediatric central nervous system malignancy and the most common primary tumor of the posterior fossa in children.
  • This highly malignant neoplasm occurs more frequently in males and usually before 10 years of age.
  • Clinical symptoms and signs are generally brief, typically less than 3 months in duration, and reflect the strong predilection of this tumor to arise within the cerebellum, most often in the vermis.
  • Surgical resection, radiation therapy, and chemotherapy have substantially lowered the mortality associated with this tumor, with 5-year survival rates now commonly well above 50%.
  • Still, both dissemination at the time of diagnosis and recurrence remain obstacles in achieving a cure.
  • The tumor has characteristic hyperattenuation on unenhanced computed tomographic scans that reflects the high nuclear-cytoplasmic ratio seen at histologic analysis.
  • The tumor typically appears heterogeneous on images, findings that are related to cyst formation, hemorrhage, and calcification and that are even more pronounced with magnetic resonance (MR) imaging.
  • Evidence of leptomeningeal metastatic spread is present in 33% of all cases at the time of diagnosis and is well evaluated with contrast-enhanced MR imaging of the brain and the spine.
  • With continued research, treatment of these common neoplasms should improve, perhaps even achieving a cure in the future.
  • [MeSH-major] Cerebellar Neoplasms / radiography. Magnetic Resonance Imaging. Medulloblastoma / radiography. Tomography, X-Ray Computed
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Infant. Male. Meninges / pathology. Middle Aged. Neoplasm Invasiveness. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Medulloblastoma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14615567.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 102
  •  go-up   go-down


16. Corns R, Crocker M, Kumar A, Salisbury J, Tolias C, Sadler G, Hill M: Low grade cerebellar T-cell lymphoma: a novel response to treatment; a case report. Acta Neurochir (Wien); 2010 Jun;152(6):1075-7
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low grade cerebellar T-cell lymphoma: a novel response to treatment; a case report.
  • We present a case developing in a previously fit young woman presenting with symptoms of raised intracranial pressure and found on CT to have a cerebellar mass.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Cerebellar Neoplasms / drug therapy. Cerebellar Neoplasms / radiotherapy. Cranial Irradiation. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / radiotherapy. Methotrexate / therapeutic use
  • [MeSH-minor] Adult. Antineoplastic Agents, Hormonal / therapeutic use. Biomarkers, Tumor / analysis. Biopsy. Cerebellum / pathology. Combined Modality Therapy. Dexamethasone / therapeutic use. Dose-Response Relationship, Drug. Female. Humans. Infusions, Intravenous. Ki-67 Antigen / analysis. Magnetic Resonance Imaging. Neurologic Examination. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19936608.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 7S5I7G3JQL / Dexamethasone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


17. Yamada SM, Hayashi Y, Takahashi H, Teramoto A, Matsumoto K, Yamada S: Histological and genetic diagnosis of gliomatosis cerebri: case report. J Neurooncol; 2001 May;52(3):237-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliomatosis cerebri is considered grade III astrocytoma because of the short survival period of patients with this tumor, while the tumor histologically consists of widespread low grade astrocytoma cells.
  • The authors tried to clarify this discrepancy by applying genetic analysis of the tumor.
  • A 29-year-old man originally presented with mild headache and showed diffuse high intensity areas in both hemispheres and in the cerebellum by T2-weighted magnetic resonance imaging (MRI) without gadolinium-dimeglumine (Gd)-enhancement in T1-weighted imaging.
  • Seven months after temporary improvement following irradiation and chemotherapy, he developed progressive mental deterioration, and died in one year after the surgery.
  • At this time T1-weighted imaging showed Gd-enhanced lesions with enlargement only of the cerebellar tumor.
  • Genetic analysis demonstrated positive FGFR 1 and less FGFR 2 mRNA in the tumor tissue, and FGFR 1 mRNA was beta type dominant.
  • These results indicated that the genetic features of this tumor are similar to those of glioblastoma multiforme concerning FGFR expression.
  • The authors conclude that genetic investigation of the tumor tissue is required to predict the prognosis of gliomatosis cerebri patients, in addition to imaging and histological examinations.
  • [MeSH-major] Brain Neoplasms / diagnosis. Neoplasms, Neuroepithelial / diagnosis
  • [MeSH-minor] Adult. Antigens, Nuclear. Biomarkers, Tumor / genetics. Cerebellar Neoplasms / chemistry. Cerebellar Neoplasms / diagnosis. Cerebellar Neoplasms / genetics. Cerebellar Neoplasms / pathology. Cerebellar Neoplasms / surgery. Combined Modality Therapy. Contrast Media. Fatal Outcome. Gadolinium DTPA. Humans. Magnetic Resonance Imaging. Male. Neoplasm Proteins / genetics. Nuclear Proteins / analysis. RNA, Messenger / analysis. RNA, Neoplasm / analysis. Receptor Protein-Tyrosine Kinases / genetics. Receptor, Fibroblast Growth Factor, Type 1. Receptor, Fibroblast Growth Factor, Type 2. Receptors, Fibroblast Growth Factor / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroradiology. 1999 Sep;41(9):650-3 [10525765.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(8):755-62 [9810441.001]
  • [Cites] Scott Med J. 1998 Jun;43(3):84-6 [9682295.001]
  • [Cites] Cancer. 1996 Oct 15;78(8):1789-93 [8859193.001]
  • [Cites] AJR Am J Roentgenol. 1993 Oct;161(4):859-62 [8372774.001]
  • [Cites] Clin Neuropathol. 1985 Jul-Aug;4(4):135-48 [4053456.001]
  • [Cites] Neuroradiology. 1996 Jul;38(5):444-8 [8837088.001]
  • [Cites] Radiology. 1996 Mar;198(3):831-5 [8628879.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):484-8 [8290551.001]
  • [Cites] Pediatr Neurol. 1999 Feb;20(2):148-51 [10082346.001]
  • [Cites] Acta Radiol. 1997 May;38(3):381-90 [9191428.001]
  • [Cites] Surg Neurol. 1991 Dec;36(6):431-40 [1759182.001]
  • [Cites] Brain Tumor Pathol. 1998;15(2):111-6 [10328549.001]
  • [Cites] Eur J Radiol. 1998 Oct;28(3):226-9 [9881257.001]
  • [Cites] Glia. 1999 Oct;28(1):66-76 [10498824.001]
  • [Cites] No To Shinkei. 1996 Apr;48(4):363-70 [8679334.001]
  • (PMID = 11519853.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / Biomarkers, Tumor; 0 / Contrast Media; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptors, Fibroblast Growth Factor; EC 2.7.10.1 / FGFR1 protein, human; EC 2.7.10.1 / FGFR2 protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 1; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 2; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


18. Wach M, Dmoszyńska A, Wasik-Szczepanek E, Skomra D: [Unusual cases of non-Hodgkin's lymphomas--case reports]. Pol Arch Med Wewn; 2000 Mar-Apr;103(3-4):205-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present three of them for the first time in Poland.
  • CT scans revealed the presence of tumor in the temporo-occipital region.
  • Co60--therapy of these region was applied after the operation with good response.
  • Case 3: a 51-year old woman was admitted to the hospital with diagnosis: anaplastic non-Hodgkin lymphoma B-cell type high malignancy established after the double histopathological examination of lymph nodes and biopsy of the lung.
  • She died after 6 months since the beginning of the relapse despite intensive chemotherapy.
  • CT scans of the brain revealed leucaemic infiltrations of the hemispheres and cerebellum.
  • The patient died despite intensive therapy due to rising progressive multiorgan failure.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adult. Brain Neoplasms / diagnostic imaging. Brain Neoplasms / surgery. Fatal Outcome. Female. Humans. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / therapy. Male. Middle Aged. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11236249.001).
  • [Journal-full-title] Polskie Archiwum Medycyny Wewnetrznej
  • [ISO-abbreviation] Pol. Arch. Med. Wewn.
  • [Language] pol
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


19. Inoue T, Kanamori M, Sonoda Y, Watanabe M, Sasajima T, Kamisato N, Kumabe T, Tominaga T: [Glioblastoma multiforme developing separately from the initial lesion 9 years after successful treatment for gliomatosis cerebri: a case report]. No Shinkei Geka; 2008 Aug;36(8):709-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Glioblastoma multiforme developing separately from the initial lesion 9 years after successful treatment for gliomatosis cerebri: a case report].
  • We report a case of histologically confirmed glioblastoma multiforme in the cerebellar vermis which occurred 9 years after treatment for gliomatosis cerebri.
  • She received 60 Gy hyperfractionated irradiation to the whole brain, and the lesion responded partially.
  • The patient remained stable for 4 years, but T2-weighted MR imaging 5 years after the initial treatment showed enlargement of the hyperintense area.
  • She received nimustine hydrochloride chemotherapy, and again partial response was observed. However.
  • T1-weighted MR imaging after administration of gadolinium-diethylenetriaminepenta-acetic acid detected enhanced lesions in the cerebellar vermis, cerebellar hemisphere, and left posterior limb of the internal capsule 9 years after the initial treatment, although no abnormal findings were observed on initial and follow-up MR imaging.
  • She underwent subtotal removal of the lesion in the cerebellar vermis.
  • The surgical specimens were characterized by dense proliferation of atypical tumor cells with scattered mitosis and endothelial proliferation.
  • The patient received gamma knife irradiation for the remnant lesion in the cerebellar vermis, and the lesions in the cerebellar hemisphere and left posterior limb of the internal capsule, and chemotherapy with temozolomide.
  • However, multiple enhanced lesions were detected in the cerebellar vermis 2 months after the start of the temozolomide chemotherapy, and she died 8 months later.
  • This case suggests that glioblastoma multiforme could develop in the long term after initial treatment for gliomatosis cerebri, and in a location separate from the initial lesion.
  • [MeSH-major] Brain Neoplasms / therapy. Cerebellum. Glioblastoma / therapy. Neoplasms, Neuroepithelial / therapy. Neoplasms, Second Primary
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Dose Fractionation. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Radiosurgery. Time Factors

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18700534.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 12
  •  go-up   go-down


20. Kano T, Ikota H, Wada H, Iwasa S, Kurosaki S: A case of an anaplastic ependymoma with gliosarcomatous components. Brain Tumor Pathol; 2009;26(1):11-7
Genetic Alliance. consumer health - Anaplastic Ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography revealed a large cystic lesion with a mural nodule-like mass homogeneously enhanced with contrast medium in the right cerebellum.
  • The tumor was removed, and pathological studies revealed a cerebellar astrocytoma corresponding to World Health Organization grade II.
  • When she was 35 years old, or 6 years after the surgery, magnetic resonance imaging revealed a recurrence of the tumor in the right cerebellum, and subtotal removal of the recurrent tumor was performed.
  • Chemotherapy (Paraplatin and VePeside-S) and focal radiation therapy at 60 Gy were administered following surgery.
  • Thereafter, at 39 years of age, or 4 years after radiation therapy, magnetic resonance imaging again revealed a recurrence of the tumor, which was heterogeneously enhanced with gadoliniumdiethylenetriamine pentaacetic acid in the right cerebellum.
  • Subtotal removal of the tumor was performed; pathological studies revealed an anaplastic ependymoma with sarcomatous components.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Ependymoma / pathology. Gliosarcoma / pathology
  • [MeSH-minor] Adult. Astrocytoma / pathology. Astrocytoma / surgery. Female. Glial Fibrillary Acidic Protein / metabolism. Headache / etiology. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Neoplasm Recurrence, Local. Paraffin Embedding. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19408092.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


21. Shu XH, Li H, Sun Z, Wu ML, Ma JX, Wang JM, Wang Q, Sun Y, Fu YS, Chen XY, Kong QY, Liu J: Identification of metabolic pattern and bioactive form of resveratrol in human medulloblastoma cells. Biochem Pharmacol; 2010 May 15;79(10):1516-25
Hazardous Substances Data Bank. RESVERATROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cell lysates and condition media of UW228-3 cells with or without 100 microM resveratrol treatment were analyzed by HPLC and LC/MS which revealed (1) that resveratrol was chemically unstable and the spontaneous generation of cis-resveratrol reduced resveratrol's anti-medulloblastoma efficacy and (2) that resveratrol monosulfate was the major metabolite of the cells.
  • The overall levels of the three brain-associated sulfotransferases (SULT1A1, 1C2 and 4A1) were low in medulloblastoma cells in vivo and in vitro in comparison with that in human noncancerous and rat normal cerebella; resveratrol could more or less up-regulate the production of these enzymes in UW228-3 cells but their overall level was still lower than that in normal cerebellum tissue.
  • Our study thus demonstrated for the first time that trans-resveratrol is the bioactive form in medulloblastoma cells in which the expression of brain-associated SULTs was down-regulated, resulting in the increased intracellular bioavailability and anti-medulloblastoma efficacy of trans-resveratrol.
  • [MeSH-major] Antineoplastic Agents / metabolism. Antineoplastic Agents / pharmacokinetics. Cerebellar Neoplasms / drug therapy. Medulloblastoma / drug therapy. Stilbenes / pharmacokinetics
  • [MeSH-minor] Adolescent. Animals. Biotransformation. Blotting, Western. Cell Line, Tumor. Child. Chromatography, High Pressure Liquid. Humans. Rats. Reverse Transcriptase Polymerase Chain Reaction. Sulfotransferases / metabolism. Young Adult

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20105429.001).
  • [ISSN] 1873-2968
  • [Journal-full-title] Biochemical pharmacology
  • [ISO-abbreviation] Biochem. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Stilbenes; EC 2.8.2.- / Sulfotransferases; Q369O8926L / resveratrol
  •  go-up   go-down


22. Benesch M, Wagner S, Berthold F, Wolff JE: Primary dissemination of high-grade gliomas in children: experiences from four studies of the Pediatric Oncology and Hematology Society of the German Language Group (GPOH). J Neurooncol; 2005 Apr;72(2):179-83
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data concerning tumor dissemination are available from 324 patients.
  • RESULTS: A total of 10 patients (3.1%) (anaplastic astrocytoma: n=3, glioblastoma multiforme: n=6, diffuse intrinsic pontine glioma: n=1) had primary tumor dissemination.
  • The most frequent primary tumor sites were the cortex (n=4), followed by the ventricles (n=2), cerebellum (n=1), spinal cord (n=1), and pons (n=1).
  • Following surgery eight patients received local radiotherapy and eight additional chemotherapy.
  • Median progression-free and overall survival was 0.8 years (95% CI 0.2-1.4) and 1.5 years (95% CI 0.67-2.29) for patients with primary tumor dissemination, respectively, with no statistically significant differences between the group with and the group without primary tumor dissemination.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / pathology. Central Nervous System Neoplasms / therapy. Glioma / pathology. Glioma / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / analogs & derivatives. Disease-Free Survival. Etoposide / administration & dosage. Female. Humans. Male. Neoplasm Invasiveness. Radiotherapy. Retrospective Studies. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1986 Aug;19(2):247-51 [3748352.001]
  • [Cites] Ann Neurol. 1987 Sep;22(3):355-64 [2823687.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3569-72 [12552957.001]
  • [Cites] Neurology. 1991 Jan;41(1):46-50 [1985295.001]
  • [Cites] J Clin Oncol. 1987 Aug;5(8):1221-31 [3040919.001]
  • [Cites] Neurosurgery. 1992 Jan;30(1):64-71 [1738457.001]
  • [Cites] J Neurooncol. 1989 Jul;7(2):165-77 [2550594.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):112-23 [7799011.001]
  • [Cites] Ann Neurol. 1985 Aug;18(2):217-21 [4037762.001]
  • [Cites] Cancer. 1990 Jun 15;65(12):2771-8 [2160318.001]
  • [Cites] Ann Neurol. 1983 Aug;14(2):177-82 [6625534.001]
  • [Cites] Cancer. 1997 Aug 1;80(3):497-504 [9241084.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Acta Neurochir (Wien). 1994;126(2-4):84-92 [8042560.001]
  • [Cites] Br J Cancer. 2002 Oct 21;87(9):945-9 [12434281.001]
  • [Cites] N Engl J Med. 1993 Jun 17;328(24):1725-31 [8388548.001]
  • [Cites] N Engl J Med. 1994 Dec 1;331(22):1500-7 [7969301.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):264-71 [11815986.001]
  • [Cites] Cancer. 2000 Nov 15;89(10):2131-7 [11066055.001]
  • [Cites] Neurosurgery. 1990 Oct;27(4):516-21; discussion 521-2 [2172859.001]
  • [Cites] Cancer. 1999 Oct 1;86(7):1347-53 [10506724.001]
  • [Cites] J Neurooncol. 2003 Sep;64(3):239-47 [14558599.001]
  • (PMID = 15925999.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; H64JRU6GJ0 / trofosfamide
  •  go-up   go-down


23. Oliveira AM, Scheithauer BW, Salomao DR, Parisi JE, Burger PC, Nascimento AG: Primary sarcomas of the brain and spinal cord: a study of 18 cases. Am J Surg Pathol; 2002 Aug;26(8):1056-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Median tumor size was 4 cm (range 1.3-8 cm).
  • Fifteen tumors arose in the cerebrum (83%), two in the cerebellum, and one in the spinal cord.
  • Histopathologically, the most common tumor types included fibrosarcoma (six), malignant fibrous histiocytoma (five), and undifferentiated sarcoma (three).
  • All patients had subtotal to gross total tumor resection; 16 also received radiotherapy and/or chemotherapy.
  • Twelve tumors (67%) were high-grade.
  • Nine patients died of the disease, eight with high-grade tumors.
  • Survival at 5 years for patients with high-grade tumors was 28% compared with 83% for those with low-grade neoplasms (p = 0.03).
  • [MeSH-major] Brain Neoplasms / pathology. Sarcoma / pathology. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Cerebellar Neoplasms / pathology. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis


24. Szathmari A, Thiesse P, Galand-desmé S, Mottolese C, Bret P, Jouanneau E, Guyotat J, Lion-François L, Frappaz D: Correlation between pre- or postoperative MRI findings and cerebellar sequelae in patients with medulloblastomas. Pediatr Blood Cancer; 2010 Dec 15;55(7):1310-6
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between pre- or postoperative MRI findings and cerebellar sequelae in patients with medulloblastomas.
  • INTRODUCTION: Immediate and delayed cerebellar dysfunction may be expected after surgical resection of a medulloblastoma.
  • MATERIAL AND METHODS: The data of 31 patients in continuous complete remission after removal of medulloblastoma, irradiation and chemotherapy, were retrospectively reviewed.
  • Magnetic Resonance Imaging (MRI) was analyzed for the following items: preoperative MRI (ratio of the surface of the tumor/posterior fossa, presence of ventricular dilatation or tonsilar hernia, involvement of the dentate nucleus) and delayed post-operative MRI (amount of cerebellar parenchyma removed, degree of cerebellar atrophy, presence of T1 hypointense regions in remaining cerebellar area and removal of region containing dentate nucleus).
  • These data were correlated with immediate and long-term cerebellar syndrome and daily life repercussions.
  • RESULTS: On preoperative MRI, the ratio of the surface of the tumor/posterior fossa and the presence of tonsilar hernia were significantly correlated with long-term sequelae on speech (respectively P = 0.027 and P = 0.05).
  • On delayed MRI, cerebellar atrophy was inversely correlated with ability to sustain daily tasks (P = 0.002).
  • Hypointense T1 territory in remaining cerebellar parenchyma significantly correlated with immediate post-operative cerebellar syndrome (P = 0.01) and showed a tendency for post-operative mutism (P = 0.087) but was not correlated with any long-term sequelae.
  • CONCLUSION: Increased cranial pressure on initial MRI and cerebellar atrophy detected on subsequent MRI studies correlated with immediate and long-term cerebellar sequelae.
  • [MeSH-major] Cerebellar Neoplasms / surgery. Magnetic Resonance Imaging. Medulloblastoma / surgery. Postoperative Complications
  • [MeSH-minor] Adolescent. Adult. Atrophy. Cerebellum / pathology. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Intracranial Hypertension / etiology. Intracranial Hypertension / pathology. Male. Young Adult

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20981689.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Yamada K, Takeshima H, Sakurama T, Kuratsu J: Secondary cervical dystonia following stereotactic radiosurgery in a patient with thalamic glioma. Surg Neurol; 2007 Dec;68(6):665-70
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE DESCRIPTION: A 27-year-old woman complaining of headache and left motor weakness was found to have a thalamic tumor on the right side.
  • Histopathologically, tumor samples manifested features of anaplastic astrocytoma.
  • She underwent stereotactic radiosurgery in addition to the conventional radiation and chemotherapy.
  • Sixteen months postoperatively, the patient developed forced head tilting to the left side combined with chin lift.
  • Irregular-shaped lesion involving the thalamus, lenticular nuclei, midbrain, pons, and cerebellum was presented on magnetic resonance images.
  • Steroid therapy effectively diminished the lesion size, and her abnormal head posturing was gradually ameliorated (TWSTRS severity scale = 3).
  • [MeSH-major] Brain Neoplasms / surgery. Glioma / surgery. Postoperative Complications / etiology. Radiosurgery / adverse effects. Torticollis / etiology
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Necrosis. Thalamus / pathology. Thalamus / surgery


26. Hadjipanayis CG, Kondziolka D, Gardner P, Niranjan A, Dagam S, Flickinger JC, Lunsford LD: Stereotactic radiosurgery for pilocytic astrocytomas when multimodal therapy is necessary. J Neurosurg; 2002 Jul;97(1):56-64
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiosurgery for pilocytic astrocytomas when multimodal therapy is necessary.
  • OBJECT: The goal of this study was to examine the role of stereotactic radiosurgery in the treatment of patients with recurrent or unresectable pilocytic astrocytomas.
  • METHODS: During a 13-year interval, 37 patients (median age 14 years) required multimodal treatment of recurrent or unresectable pilocytic astrocytomas.
  • Tumors involved the brainstem in 18 patients, cerebellum in three, thalamus in five, temporal lobe in four, and parietal lobe in two, as well as the hypothalamus, optic tract, corpus callosum, insular cortex, and third ventricle in one patient each.
  • Multimodal treatment included fractionated radiation therapy in 10 patients, stereotactic intracavitary irradiation of tumor in four, chemotherapy in two, cyst drainage in six, ventriculoperitoneal shunt placement in three, and additional cytoreductive surgery in four.
  • Tumor volumes varied from 0.42 to 25 cm3.
  • The median radiosurgical dose to the tumor margin was 15 Gy (range 9.6-22.5 Gy).
  • After radiosurgery, serial imaging demonstrated complete tumor resolution in 10 patients, reduced tumor volume in eight, stable tumor volume in seven, and delayed tumor progression in 12.
  • No procedure-related death was encountered.
  • Three patients died of local tumor progression.
  • Despite the favorable histological characteristics and prognosis usually associated with this neoplasm, an adverse location, recurrence, or progression of this disease requires alternative therapeutic approaches such as radiosurgery.
  • [MeSH-major] Astrocytoma / surgery. Astrocytoma / therapy. Brain Stem Neoplasms / surgery. Brain Stem Neoplasms / therapy. Radiosurgery
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Biopsy. Child. Child, Preschool. Cisplatin / administration & dosage. Combined Modality Therapy. Cysts / surgery. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis. Radiotherapy / adverse effects. Retrospective Studies. Treatment Outcome. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12134933.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


27. Benesch M, Lackner H, Sovinz P, Suppan E, Schwinger W, Eder HG, Dornbusch HJ, Moser A, Triebl-Roth K, Urban C: Late sequela after treatment of childhood low-grade gliomas: a retrospective analysis of 69 long-term survivors treated between 1983 and 2003. J Neurooncol; 2006 Jun;78(2):199-205
MedlinePlus Health Information. consumer health - Neurologic Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late sequela after treatment of childhood low-grade gliomas: a retrospective analysis of 69 long-term survivors treated between 1983 and 2003.
  • Eighty-seven patients with low-grade gliomas grouped according to tumor location (cerebellum: n=28; cerebral hemispheres: n=21; central midline: n=15; brainstem: n=12; tectum: n=5; other locations: n=6) were evaluated for tumor- and/or treatment-related late effects by analysis of medical and computer records, and personal interviews.
  • Seventy patients underwent neurosurgery, 29 patients received additional radiotherapy and 20 additional chemotherapy.
  • Median follow-up of survivors is 96 months with an overall survival of 79% (cerebellum: 89%; cerebral hemispheres: 95%; central midline: 80%; brainstem: 25%; tectum: 100%; other locations: 66%).
  • Chronic medical problems (mild ataxia to multiple severe neuroendocrine deficits) are observed in 100% of patients with brainstem/central midline tumors and in 40-50% of patients with low-grade gliomas of other locations.
  • Tumor- and treatment-related late effects are common in patients with low-grade gliomas with the most severe occurring in patients with brainstem or central midline tumors.
  • As long-term survival is excellent in patients with low-grade gliomas except for tumors located in the brainstem, future treatment studies should focus on avoiding long-term late effects.
  • [MeSH-major] Brain Neoplasms / therapy. Endocrine System Diseases / epidemiology. Glioma / therapy. Nervous System Diseases / epidemiology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / adverse effects. Austria / epidemiology. Child. Child, Preschool. Cohort Studies. Combined Modality Therapy / adverse effects. Disease-Free Survival. Female. Follow-Up Studies. Hearing Disorders / epidemiology. Hearing Disorders / etiology. Humans. Infant. Male. Radiation Injuries / epidemiology. Retrospective Studies. Survivors / statistics & numerical data. Vision Disorders / epidemiology. Vision Disorders / etiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Endocrine Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Klin Padiatr. 2004 Nov-Dec;216(6):331-42 [15565548.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):265-73 [9950497.001]
  • [Cites] Radiother Oncol. 2000 Mar;54(3):239-45 [10738082.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Oct;12(10):1823-8 [3759533.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3255-61 [12947060.001]
  • [Cites] Strahlenther Onkol. 2003 Aug;179(8):509-20 [14509949.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2792-9 [9256121.001]
  • [Cites] Pediatr Neurosurg. 2000 Sep;33(3):151-8 [11096362.001]
  • [Cites] Ann Neurol. 1994 Jul;36(1):48-54 [8024261.001]
  • [Cites] Childs Nerv Syst. 1995 Aug;11(8):443-8 [7585679.001]
  • [Cites] Eur J Cancer. 1998 Apr;34(5):694-8 [9713276.001]
  • [Cites] Cancer. 1984 Jul 1;54(1):135-8 [6722738.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1084-92 [12569610.001]
  • [Cites] Cancer. 1988 Feb 15;61(4):635-42 [3338030.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5198-204 [16051961.001]
  • [Cites] Pediatr Neurosurg. 2001 Oct;35(4):173-80 [11694794.001]
  • [Cites] Neuro Oncol. 2003 Jul;5(3):153-60 [12816721.001]
  • [Cites] Pediatr Neurosurg. 2000 Jan;32(1):24-9 [10765135.001]
  • [Cites] Eur J Pediatr. 1990 Sep;149(12):825-8 [2226566.001]
  • [Cites] J Neurosurg. 1995 Apr;82(4):536-47 [7897512.001]
  • [Cites] J Clin Oncol. 1991 Apr;9(4):592-9 [2066756.001]
  • [Cites] Cancer. 1982 Apr 15;49(8):1580-6 [7066864.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Jul;47(1):79-85 [9302376.001]
  • [Cites] Cancer. 1994 Sep 15;74(6):1827-34 [8082086.001]
  • [Cites] J Pediatr. 1978 Dec;93(6):903-9 [214533.001]
  • [Cites] Eur J Pediatr. 2000 Oct;159(10):750-8 [11039130.001]
  • [Cites] Arch Dis Child. 1998 Oct;79(4):334-8 [9875044.001]
  • [Cites] N Engl J Med. 1994 Dec 1;331(22):1500-7 [7969301.001]
  • [Cites] Neurology. 2005 Jul 26;65(2):212-5 [16043788.001]
  • [Cites] Childs Nerv Syst. 1999 Oct;15(10):506-13 [10550582.001]
  • [Cites] Brain Pathol. 1997 Apr;7(2):785-98 [9161729.001]
  • [Cites] Med Pediatr Oncol. 1995 Feb;24(2):104-8 [7990757.001]
  • [Cites] Semin Radiat Oncol. 2001 Apr;11(2):152-62 [11285553.001]
  • [Cites] Arch Dis Child. 1978 Apr;53(4):301-4 [417680.001]
  • (PMID = 16739030.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down






Advertisement